LLY

1,039.1

-2.04%↓

JNJ

205.81

+0.79%↑

ABBV

227.14

+0.78%↑

UNH

332.31

+1.72%↑

AZN

91.07

+0.24%↑

LLY

1,039.1

-2.04%↓

JNJ

205.81

+0.79%↑

ABBV

227.14

+0.78%↑

UNH

332.31

+1.72%↑

AZN

91.07

+0.24%↑

LLY

1,039.1

-2.04%↓

JNJ

205.81

+0.79%↑

ABBV

227.14

+0.78%↑

UNH

332.31

+1.72%↑

AZN

91.07

+0.24%↑

LLY

1,039.1

-2.04%↓

JNJ

205.81

+0.79%↑

ABBV

227.14

+0.78%↑

UNH

332.31

+1.72%↑

AZN

91.07

+0.24%↑

LLY

1,039.1

-2.04%↓

JNJ

205.81

+0.79%↑

ABBV

227.14

+0.78%↑

UNH

332.31

+1.72%↑

AZN

91.07

+0.24%↑

Inicio・Lista de Acciones・Cassava Sciences Inc

Cassava Sciences Inc

Abierto

SectorSanidad

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

2.88

Máximo

3.06

Métricas clave
By Trading Economics
Ingresos	33M -11M
Ventas	840K 840K
BPA	-0.22
Margen de beneficios	-1,286.548
Empleados	30
EBITDA	35M -11M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+164.03% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-4.3M 142M
Apertura anterior	3
Cierre anterior	3

Noticias sobre sentimiento de mercado

By Acuity

67%

33%

343 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bearish Evidence

1.56 / 1.7 Soporte y Resistencia

Cassava Sciences Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

2 dic 2025, 17:29 UTC

Principales Movimientos del Mercado

Adquisiciones, fusiones, absorciones

Laurentian Bank Shares Hit Two-Year High on Plans for Break-Up, Takeover

2 dic 2025, 16:21 UTC

Ganancias

Scotiabank Aiming for Earnings Growth After Capital Markets Buoy Results in Latest Quarter -- Update

2 dic 2025, 16:18 UTC

Ganancias

Correction to Scotiabank Quarterly Earnings Buoyed Article

2 dic 2025, 23:53 UTC

Charlas de Mercado

Nikkei May Rise After Gains on Wall Street -- Market Talk

2 dic 2025, 22:48 UTC

Ganancias

Marvell's Stock Soars On Data Center Forecast -- Barrons.com

2 dic 2025, 22:12 UTC

Charlas de Mercado

Australian 3Q GDP To Show Modest Recovery In Play -- Market Talk

2 dic 2025, 22:03 UTC

Charlas de Mercado

Minerals 260's Resource Upgrade Looks Impressive -- Market Talk

2 dic 2025, 22:00 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

2 dic 2025, 22:00 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

2 dic 2025, 22:00 UTC

Charlas de Mercado

Fletcher Building Loses Bull Due to Tame Housing-Market Recovery -- Market Talk

2 dic 2025, 21:56 UTC

Ganancias

Marvell's Stock Drops As Outlook Fails to Impress -- Barrons.com

2 dic 2025, 21:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

2 dic 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

2 dic 2025, 21:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

2 dic 2025, 21:44 UTC

Ganancias

Marvell's Stock Drops As Outlook Fails to Impress -- Barrons.com

2 dic 2025, 21:38 UTC

Charlas de Mercado

Sky Network TV Has Path to Grow Dividend by 33% -- Market Talk

2 dic 2025, 21:19 UTC

Ganancias

Marvell's Stock Drops As Outlook Fails to Impress -- Barrons.com

2 dic 2025, 20:06 UTC

Charlas de Mercado

Oil Futures Fall Amid Russia-Ukraine Peace Talks -- Market Talk

2 dic 2025, 19:55 UTC

Charlas de Mercado

Natural Gas Futures Fall Amid Uncertain Weather Forecasts -- Market Talk

2 dic 2025, 19:53 UTC

Charlas de Mercado

Ganancias

Global Equities Roundup: Market Talk

2 dic 2025, 19:53 UTC

Charlas de Mercado

Ganancias

Scotiabank ROE Target Viewed as Possibly Conservative -- Market Talk

2 dic 2025, 19:24 UTC

Charlas de Mercado

Analysts Project Uptick in U.S. Ethanol Stocks -- Market Talk

2 dic 2025, 19:06 UTC

Charlas de Mercado

Precious Metals Step Back After Silver Sets Record -- Market Talk

2 dic 2025, 18:27 UTC

Adquisiciones, fusiones, absorciones

Kraken to Acquire Backed Finance AG

2 dic 2025, 17:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

2 dic 2025, 17:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

2 dic 2025, 15:17 UTC

Charlas de Mercado

Natural Gas Extends Gains Amid Cold Weather -- Market Talk

2 dic 2025, 14:47 UTC

Charlas de Mercado

BOE Likely to Cut Rates Further, Weakening Sterling -- Market Talk

2 dic 2025, 14:38 UTC

Charlas de Mercado

Silver Steps Back From Record Levels -- Market Talk

2 dic 2025, 14:31 UTC

Charlas de Mercado

Ganancias

Scotiabank Strong Quarter Driven By Capital Markets Growth -- Market Talk

Comparación entre iguales

Cambio de precio

Cassava Sciences Inc previsión

Precio Objetivo

By TipRanks

164.03% repunte

Estimación a 12 Meses

Media 8 USD 164.03%

Máximo 8 USD

Mínimo 8 USD

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Cassava Sciences Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

1 ratings

Comprar

Mantener

Vender

De acuerdo con 1 analistas que ofrecen calificaciones bursátiles a para Cassava Sciences Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.56 / 1.7Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentimiento

By Acuity

343 / 374 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Cassava Sciences Inc

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.